Development
Janus Henderson Global Life Sciences Fund Class C
JFNCX
NASDAQ
| Weiss Ratings | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C+ | |||
| Company Info | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | Janus Henderson | |||
| Manager/Tenure (Years) | Andy Acker (17), Daniel Lyons (2) | |||
| Website | http://janushenderson.com | |||
| Fund Information | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | Janus Henderson Global Life Sciences Fund Class C | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Health | |||
| Inception Date | Jul 06, 2009 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | 2,500.00 | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | 0.01 | |||
| Dividends and Shares | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 0.00% | |||
| Dividend | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 1.20% | |||
| Asset Allocation | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 0.35% | |||
| Stock | 98.81% | |||
| U.S. Stock | 81.93% | |||
| Non-U.S. Stock | 16.88% | |||
| Bond | 0.01% | |||
| U.S. Bond | 0.01% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 0.31% | |||
| Convertible | 0.04% | |||
| Other Net | 0.49% | |||
| Price History | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.17% | |||
| 30-Day Total Return | -6.65% | |||
| 60-Day Total Return | -6.93% | |||
| 90-Day Total Return | -1.47% | |||
| Year to Date Total Return | -1.47% | |||
| 1-Year Total Return | -3.70% | |||
| 2-Year Total Return | 9.31% | |||
| 3-Year Total Return | 8.25% | |||
| 5-Year Total Return | 61.07% | |||
| Price | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | -- | |||
| 1-Month High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price | -- | |||
| 52-Week High Price (Date) | -- | |||
| NAV | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $56.27 | |||
| 1-Month Low NAV | $56.27 | |||
| 1-Month High NAV | $60.39 | |||
| 52-Week Low NAV | $56.27 | |||
| 52-Week Low NAV (Date) | Apr 01, 2025 | |||
| 52-Week High NAV | $70.12 | |||
| 52-Week High Price (Date) | Aug 30, 2024 | |||
| Beta / Standard Deviation | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.69 | |||
| Standard Deviation | 14.70 | |||
| Balance Sheet | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 4.95B | |||
| Operating Ratios | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.76% | |||
| Turnover Ratio | 35.00% | |||
| Performance | JFNCX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 7.61% | |||
| Last Bear Market Total Return | -8.45% | |||